Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?

SIMPLE SUMMARY: In oncology, a new era has emerged in the last ten years with the development of targeted and immune therapies. In hepatocellular carcinoma (HCC), several targeted agents (sorafenib, lenvatinib, cabozantinib, regorafenib, and ramucirumab) are approved and immunotherapy is now validat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancers (Basel)
Main Authors: Boilève, Alice, Hilmi, Marc, Delaye, Matthieu, Tijeras-Raballand, Annemilaï, Neuzillet, Cindy
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2021
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8198554/
https://ncbi.nlm.nih.gov/pubmed/34070929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112708
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki